)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Assertio
Assertio (ASRT) investor relations material
Assertio has been acquired by Zydus Lifesciences Limited
Assertio Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary8 May, 2026
Executive summary
Completed sale of all non-ROLVEDON assets to Cosette for $35M upfront plus potential earnouts; ROLVEDON is now the sole commercial product.
Entered into a merger agreement with Garda Therapeutics for $21.80 per share in cash, expected to close in Q2 2026.
Q1 2026 net loss was $18.9M, compared to $13.5M in Q1 2025; revenue declined sharply due to lower ROLVEDON and INDOCIN sales.
Financial highlights
Total revenues for Q1 2026 were $9.9M, down from $26.5M in Q1 2025, driven by a $12.6M drop in ROLVEDON sales and lower INDOCIN and Otrexup sales.
Net loss per share was $(2.93), compared to $(2.12) in Q1 2025.
Cash and short-term investments totaled $71.6M at March 31, 2026.
Operating cash flow was $8.6M, a significant improvement from $(12.5)M in Q1 2025, mainly due to working capital changes.
Outlook and guidance
Future revenues will rely solely on ROLVEDON following the asset sale; any failure to grow or maintain ROLVEDON sales would have a disproportionate adverse impact.
The company expects sufficient liquidity for at least the next 12 months, but ongoing legal expenses and settlements may be a significant cash use.
Contingent consideration from the Cosette asset sale is dependent on future milestones and may not be fully realized.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Assertio
- Annual meeting to vote on directors, equity plan, executive pay, and auditor ratification.ASRT
Proxy filing - 2026 guidance targets $110M–$125M revenue, led by ROLVEDON growth and cost discipline.ASRTQ4 2025
- Proxy seeks approval for director elections, equity plan expansion, reverse split, and auditor ratification.ASRTProxy Filing
- Proxy seeks approval for director elections, equity plan expansion, reverse split, and auditor ratification.ASRTProxy Filing
- Rolvedon drives growth as expansion and clinical initiatives position for long-term value.ASRTMaxim Group’s 2024 Healthcare Virtual Summit
- Q3 sales were $28.7M as Indocin fell, Rolvedon held steady, and margins improved.ASRTQ3 2024
- ROLVEDON growth offset Indocin decline; sales $30.7M, net loss $3.7M, cash $88.4M.ASRTQ2 2024
- Rolvedon drives growth with $60M–$100M potential, supported by strong cash flow and new leadership.ASRTSmall-Cap Growth Virtual Investor Conference
- Rolvedon growth offset Indocin decline in 2024; 2025 targets modest gains amid legal and market headwinds.ASRTQ4 2024
Assertio
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Assertio Holdings Inc. is a pharmaceutical company focused on the development, marketing, and distribution of prescription medications. The company specializes in providing treatments for patients with chronic pain, neurological disorders, and other medical conditions. Assertio's portfolio includes a range of therapies aimed at improving patient quality of life, with an emphasis on non-opioid options for pain management. The company is headquartered in Lake Forest, Illinois, and its shares are listed on the NASDAQ.